Most Trial Eligibility Criteria and Patient Baseline Characteristics Do Not Modify Treatment Effect in Trials Using Targeted Therapies for Rheumatoid Arthritis: A Meta-Epidemiological Study

• Anton Wulf Christensen,

  Affiliation The Parker Institute, Department of Rheumatology, Copenhagen University Hospitals, Bispebjerg and Frederiksberg, Frederiksberg, Denmark

  ⨯
• Simon Tarp,

  Affiliation The Parker Institute, Department of Rheumatology, Copenhagen University Hospitals, Bispebjerg and Frederiksberg, Frederiksberg, Denmark

  ⨯
• Daniel E. Furst,

  Affiliation David Geffen School of Medicine, University of California in Los Angeles, Los Angeles, California, United States of America

  ⨯
• Anna Døssing,

  Affiliation The Parker Institute, Department of Rheumatology, Copenhagen University Hospitals, Bispebjerg and Frederiksberg, Frederiksberg, Denmark

  ⨯
• Kirstine Amris,

  Affiliation The Parker Institute, Department of Rheumatology, Copenhagen University Hospitals, Bispebjerg and Frederiksberg, Frederiksberg, Denmark

  ⨯
• Henning Bliddal,

  Affiliation The Parker Institute, Department of Rheumatology, Copenhagen University Hospitals, Bispebjerg and Frederiksberg, Frederiksberg, Denmark

  ⨯
• Peter C. Taylor,

  Affiliation Kennedy Institute of Rheumatology: Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Botnar Research Centre, United Kingdom

  ⨯
• Robin Christensen

  * E-mail: robin.christensen@regionh.dk

  Affiliation The Parker Institute, Department of Rheumatology, Copenhagen University Hospitals, Bispebjerg and Frederiksberg, Frederiksberg, Denmark

  ⨯